Stocktoria
TREACE MEDICAL CONCEPTS, INC. TMCI
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-04-23
TREACE MEDICAL CONCEPTS, INC. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M | $57.4M |
| Gross profit | $169.8M | $168.3M | $151.9M | $116.3M | $77.5M | $44.9M |
| R&D expense | $20.3M | $20.6M | $15.4M | $13.6M | $10.2M | $5.8M |
| Operating income | -$54.2M | -$55.7M | -$51.4M | -$34.8M | -$16.5M | $855,000 |
| Interest expense | $5.3M | $5.3M | $5.2M | $4.4M | $4.1M | $2.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.0M | -$55.7M | -$49.5M | -$42.8M | -$20.6M | -$3.7M |
| EPS (diluted) | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 | $-0.12 |
| Operating cash flow | -$16.0M | -$37.2M | -$34.6M | -$30.6M | -$17.2M | -$4.5M |
| Free cash flow | -$29.5M | -$48.8M | -$46.0M | -$45.5M | -$19.9M | -$5.6M |
| Cash & equivalents | $10.7M | $11.3M | $13.0M | $19.5M | $105.8M | $18.1M |
| Inventory | $36.0M | $39.3M | $29.2M | $19.3M | $10.6M | $7.8M |
| Total assets | $190.6M | $217.1M | $251.9M | $159.0M | $140.8M | $41.8M |
| Total liabilities | $103.2M | $104.2M | $114.0M | $98.5M | $47.7M | $41.0M |
| Shareholders' equity | $87.3M | $112.9M | $137.9M | $60.5M | $93.1M | $776,000 |
Growth · year-over-year · Revenue CAGR 30%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +1.6% | +11.9% | +31.9% | +50.2% | +64.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.